Company intelligence / Profile preview

AlonBio

Ownership: Private
Development stage: Phase 2

Overview

AlonBio aims to develop novel targeted anti-cancer therapies to improve and extend the lives of patients with advanced cancers. Specific clinical results are not disclosed publicly as of May 2025[1].

Therapeutic areas: Oncology
Modalities: Not explicitly stated; likely targeted therapies for cancer (inferred from "targeted anti-cancer approach")
Industry: Biotech

Drug pipeline

1 asset

BKT300

Preclinical

Beyond the preview

Go deeper on AlonBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlonBio.

Explore the full profile